Bristol-Myers Squibb (BMY) Tops Q4 EPS by 9c, Offers FY19 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. ZETA
9. DAL
10. TMUS

Go back to Bristol-Myers Squibb (BMY) Tops Q4 EPS by 9c, Offers FY19 Guidance

Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results

January 24, 2019 6:59 AM EST

Increases Fourth Quarter Revenues 10% to $6.0 Billion, 9% for Full Year to $22.6 Billion Posts Fourth Quarter GAAP EPS of $0.73 and Non-GAAP EPS of $0.94 Announces Strategic Acquisition of Celgene Corporation Announces Voluntary Withdrawal of U.S. Application for Opdivo Plus Low-Dose Yervoy for Treatment of First-Line Lung Cancer in Patients with Tumor Mutational Burden 10 Mutations/Megabase, following discussions with the U.S. FDA Additional Opdivo Plus Yervoy Approvals in Europe for Patients with Renal Cell Carcinoma... More